DK1729773T3 - 8-hydroxy-5-[(hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]-ethyl]-2-(1H)-quinolinon-monohydrochlorid i krystallinsk form og fremgangsmåde til fremstilling heraf - Google Patents

8-hydroxy-5-[(hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]-ethyl]-2-(1H)-quinolinon-monohydrochlorid i krystallinsk form og fremgangsmåde til fremstilling heraf

Info

Publication number
DK1729773T3
DK1729773T3 DK05730069T DK05730069T DK1729773T3 DK 1729773 T3 DK1729773 T3 DK 1729773T3 DK 05730069 T DK05730069 T DK 05730069T DK 05730069 T DK05730069 T DK 05730069T DK 1729773 T3 DK1729773 T3 DK 1729773T3
Authority
DK
Denmark
Prior art keywords
hydroxy
methylethyl
methoxyphenyl
ethyl
amino
Prior art date
Application number
DK05730069T
Other languages
Danish (da)
English (en)
Inventor
Fausto Pivetti
Roberto Pighi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1729773(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of DK1729773T3 publication Critical patent/DK1729773T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05730069T 2004-03-24 2005-03-24 8-hydroxy-5-[(hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]-ethyl]-2-(1H)-quinolinon-monohydrochlorid i krystallinsk form og fremgangsmåde til fremstilling heraf DK1729773T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24
PCT/EP2005/003144 WO2005089760A1 (en) 2004-03-24 2005-03-24 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation

Publications (1)

Publication Number Publication Date
DK1729773T3 true DK1729773T3 (da) 2008-10-20

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05730069T DK1729773T3 (da) 2004-03-24 2005-03-24 8-hydroxy-5-[(hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]-ethyl]-2-(1H)-quinolinon-monohydrochlorid i krystallinsk form og fremgangsmåde til fremstilling heraf

Country Status (30)

Country Link
US (1) US20070197586A1 (es)
EP (1) EP1729773B1 (es)
JP (1) JP2007530489A (es)
KR (1) KR20070001946A (es)
CN (2) CN1929840B (es)
AR (1) AR048339A1 (es)
AT (1) ATE399552T1 (es)
AU (1) AU2005224032A1 (es)
BR (1) BRPI0508213A (es)
CA (1) CA2560650A1 (es)
CY (1) CY1108323T1 (es)
DE (1) DE602005007871D1 (es)
DK (1) DK1729773T3 (es)
EA (1) EA010128B1 (es)
ES (1) ES2309739T3 (es)
HR (1) HRP20080495T3 (es)
IL (1) IL178227A0 (es)
MA (1) MA28549B1 (es)
MX (1) MXPA06010515A (es)
NO (1) NO20064274L (es)
NZ (1) NZ550010A (es)
PE (1) PE20060159A1 (es)
PL (1) PL1729773T3 (es)
PT (1) PT1729773E (es)
RS (1) RS50602B (es)
SI (1) SI1729773T1 (es)
TN (1) TNSN06249A1 (es)
UA (1) UA86221C2 (es)
WO (1) WO2005089760A1 (es)
ZA (1) ZA200607907B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO2005013945A2 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride

Also Published As

Publication number Publication date
US20070197586A1 (en) 2007-08-23
JP2007530489A (ja) 2007-11-01
ZA200607907B (en) 2008-04-30
CN1929840B (zh) 2010-12-08
AR048339A1 (es) 2006-04-19
AU2005224032A1 (en) 2005-09-29
CA2560650A1 (en) 2005-09-29
DE602005007871D1 (de) 2008-08-14
UA86221C2 (en) 2009-04-10
CY1108323T1 (el) 2014-02-12
KR20070001946A (ko) 2007-01-04
ATE399552T1 (de) 2008-07-15
RS50602B (sr) 2010-05-07
ES2309739T3 (es) 2008-12-16
EP1729773A1 (en) 2006-12-13
NO20064274L (no) 2006-10-13
SI1729773T1 (sl) 2008-10-31
MXPA06010515A (es) 2007-03-30
PT1729773E (pt) 2008-09-29
WO2005089760A1 (en) 2005-09-29
PL1729773T3 (pl) 2008-12-31
EA010128B1 (ru) 2008-06-30
EP1729773B1 (en) 2008-07-02
CN101812017A (zh) 2010-08-25
IL178227A0 (en) 2006-12-31
CN1929840A (zh) 2007-03-14
HRP20080495T3 (en) 2008-11-30
BRPI0508213A (pt) 2007-07-17
EA200601531A1 (ru) 2007-04-27
NZ550010A (en) 2010-08-27
MA28549B1 (fr) 2007-04-03
PE20060159A1 (es) 2006-04-04
TNSN06249A1 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
PL1797037T3 (pl) Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu
DK1729773T3 (da) 8-hydroxy-5-[(hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]-ethyl]-2-(1H)-quinolinon-monohydrochlorid i krystallinsk form og fremgangsmåde til fremstilling heraf
IL186820A0 (en) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
NL300784I2 (nl) Ketorolac, of het trometamolzout ervan, en fenylefrine, of het hydrochloridezout ervan
IL174942A0 (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl] benzamide, preparation method thereof and applications of same in therapeutics
BRPI0516905A (pt) processo para a preparação de um derivado n-[2-(2-piridinil)etil]carboxamida e compostos
IL181792A0 (en) Process and intermediates for preparing cysteine protease inhibitors
IL164400A (en) Derivatives of n - [phenyl(piperidin-2 - yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics
SG133452A1 (en) Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
EE200300469A (et) N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul
ZA200509103B (en) Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamideor salts thereof
GB0421525D0 (en) Inhibitors of protein kineses
EP1812012A4 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE
PL379385A1 (pl) Nowe związki 2-pirydynyloetylobenzamidowe
IL213615A0 (en) N-(5-substituted-2-nitrophenyl)amine derivatives and methods for the preparation of 6-substituted-1-methyl-1-h-benzimidazole derivatives utilizing the same
EA200900926A1 (ru) Способ получения моногидрохлорида 8-гидрокси-5-[(1r)-1-гидрокси-2[[(1r)-2-(4-метоксифенил)-1-метилэтил]амино]этил]-2(1h)-хинолинона
IL182277A0 (en) Method and intermediates for the preparation of derivatives of n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulphonamide
ITMI20042204A1 (it) Mezzi di connessione tra asta e testa a croce per una macchina alternativa
EP1880991A4 (en) PROCESS FOR SEPARATION AND RECOVERY OF OPTO-ACTIVE AMINO ACID AMIDE
ITVI20050224A1 (it) Testa di nastro perfezionata per telai tessili a pinze e procedimento per la sua realizzazione
FI20050726A (fi) Menetelmä kahden metallikappaleen liitokseen soveltuvan juotteen valmistamiseksi, juote sekä juotteen käyttö
ITMI20040944A1 (it) Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
ZA200709776B (en) Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
EP1739077A4 (en) PROCESS FOR THE PRODUCTION OF NON-NATURAL AMINO ACIDS AND INTERMEDIATES THEREFOR
ITPO20030002A1 (it) Orecchino perfezionato e metodo per la sua applicazione